Genomic Sequencing + Cancer Immunoediting = Potential for More Precise Immunotherapies

Share this content:

(ChemotherapyAdvisor) – Cancer immunoediting of a mutation expressed in highly immunogenic sarcomas derived from immunodeficient mice occurs via a T-cell-dependent process, a study published in Nature online February 8 has found.

The sarcomas phenotypically resemble nascent primary tumor cells. The process promotes outgrowth of preexisting tumor cell clones that lack the highly antigenic mutant spectrin-β2 as well as other potential antigens.

These results “demonstrate that the strong immunogenicity of an unedited tumor can be ascribed to expression of highly antigenic mutant proteins,” wrote Robert Schreiber, PhD, of the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, and colleagues. They initially identified 3,743 genetic mutations in tumor cells.

One of the promises of genomic sequencing is that, when combined with cancer immunoediting, a vaccine may be developed that could target six or seven mutated proteins.


Video News Release (click on image to view video):

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs